Results 131 to 140 of about 802,486 (287)

Model‐based evaluation of the interaction between ritonavir‐boosted atazanavir and rifampicin in Ugandan adults with HIV

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Concomitant treatment of tuberculosis (TB) and human immunodeficiency virus (HIV) is complicated by drug‐drug interactions (DDI). This analysis aimed to characterize the DDI between ritonavir‐boosted atazanavir (ATV/r) and rifampicin in plasma and peripheral blood mononuclear cells (PBMC).
Allan Kengo   +10 more
wiley   +1 more source

Genetic predisposition to porto‐sinusoidal vascular disorder: A functional genomic‐based, multigenerational family study

open access: yesHepatology, EarlyView., 2022
A deleterious variant of FCHSD1 results in mTOR pathway overactivation and may cause porto‐sinusoidal vascular disorder (PSVD). The pedigree of the family demonstrated an autosomal dominant disease with variable expressivity. Whole‐genome sequencing and Sanger sequencing both validated the existence of the FCHSD1 variant and the heterozygosity of c ...
Jingxuan Shan   +19 more
wiley   +1 more source

Large surface proteins of hepatitis B virus containing the pre-s sequence [PDF]

open access: bronze, 1984
K.‐H. Heermann   +5 more
openalex   +1 more source

Adverse drug reactions, particularly liver disorders, drive interruptions in anti‐tuberculosis treatment: A retrospective cohort study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Adverse drug reactions (ADRs) are a key driver of missed doses of anti‐tuberculosis (TB) therapy. We aimed to determine the relative burden of ADR‐driven missed doses, the missed dose patterns associated with ADRs, and the association between specific ADRs and missed doses.
Eleanor G. Dixon   +10 more
wiley   +1 more source

Attacking the public health crisis of hepatocellular carcinoma at its roots

open access: yesHepatology, EarlyView., 2022
Abstract As the third most common cause of cancer‐related death worldwide with significant mortality rates in the United States, hepatocellular carcinoma has strong association with cirrhosis and chronic hepatitis B virus (HBV) with a growing at‐risk population from the rise in chronic liver disease from alcohol use and nonalcoholic fatty liver disease.
Hannah M. Lee   +3 more
wiley   +1 more source

Recurrent fexuprazan‐induced liver injury following unintentional re‐exposure

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Fexuprazan, a potassium‐competitive acid blocker, is increasingly used for the treatment of gastroesophageal reflux disease in South Korea. While generally well tolerated, data regarding its hepatotoxic potential are scarce. We report a case of idiosyncratic drug‐induced liver injury in a 61‐year‐old woman following 2 months of fexuprazan therapy.
Sook Jin Seong   +5 more
wiley   +1 more source

Health disparities in chronic liver disease

open access: yesHepatology, EarlyView., 2022
Abstract The syndemic of hazardous alcohol consumption, opioid use, and obesity has led to important changes in liver disease epidemiology that have exacerbated health disparities. Health disparities occur when plausibly avoidable health differences are experienced by socially disadvantaged populations.
Ani Kardashian   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy